摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Acetoxy-2-ethyl-buttersaeure-chlorid | 57865-36-8

中文名称
——
中文别名
——
英文名称
2-Acetoxy-2-ethyl-buttersaeure-chlorid
英文别名
α-Acetoxy-α-ethyl-buttersaeure-chlorid;α-Acetoxy-α-aethyl-buttersaeurechlorid;2-acetoxy-2-ehtylbutanoyl chloride;3-Carbonochloridoylpentan-3-yl acetate
2-Acetoxy-2-ethyl-buttersaeure-chlorid化学式
CAS
57865-36-8
化学式
C8H13ClO3
mdl
——
分子量
192.642
InChiKey
BGUFLYZMUUPCON-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    12
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    43.4
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors
    摘要:
    With the aim of characterizing the hydrophobic interactions between xanthines and the A1 receptor site, 1,3-dipropyl-8-substituted xanthines were synthesized. Introduction of a quaternary carbon and the conformationally restricted cyclopentyl moiety into the 8-position of xanthines enhanced the adenosine A1 antagonism. 1,3-Dipropyl-8-(3-noradamantyl)xanthine (42) was identified to be a selective and the most potent A1 receptor antagonist reported to date. Under our structure-activity relationship, the 8-substituent of xanthine antagonists and the N6-substituent of adenosine agonists appears to bind to the same region of the A1 receptor.
    DOI:
    10.1021/jm00083a018
  • 作为产物:
    描述:
    α-Acetoxy-α-ethyl-buttersaeure氯化亚砜 作用下, 以 吡啶 为溶剂, 反应 0.17h, 生成 2-Acetoxy-2-ethyl-buttersaeure-chlorid
    参考文献:
    名称:
    8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors
    摘要:
    With the aim of characterizing the hydrophobic interactions between xanthines and the A1 receptor site, 1,3-dipropyl-8-substituted xanthines were synthesized. Introduction of a quaternary carbon and the conformationally restricted cyclopentyl moiety into the 8-position of xanthines enhanced the adenosine A1 antagonism. 1,3-Dipropyl-8-(3-noradamantyl)xanthine (42) was identified to be a selective and the most potent A1 receptor antagonist reported to date. Under our structure-activity relationship, the 8-substituent of xanthine antagonists and the N6-substituent of adenosine agonists appears to bind to the same region of the A1 receptor.
    DOI:
    10.1021/jm00083a018
点击查看最新优质反应信息

文献信息

  • Chemical compounds and their use to elevate pyruvate dehydrogenase activity
    申请人:AstraZeneca AB
    公开号:US06369273B1
    公开(公告)日:2002-04-09
    The use of a compound of the formula (I): wherein: ring C is phenyl or carbon-linked heteroaryl selected from pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl; and wherein said phenyl or heteroaryl is substituted as defined herein; A—B is selected from NHCO, OCH2, SCH2, NHCH2, trans-vinylene, and ethynylene; R1 is linked to ring C at a carbon ortho to the position of A—B attachment and is defined herein; n is 1 or 2; R2 and R3 are alkyl, haloalkyl or together from cycloalkyl or halocycloalkyl as defined herein; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Salts and esters of compounds of formula (I) are also described.
    该化合物的使用公式(I):其中:环C为苯基或碳链杂环芳基,选择自吡啶基、吡嗪基、嘧啶基和吡啶吡嗪基;所述苯基或杂环芳基如本文所定义被取代;A—B选择自NHCO、OCH2、SCH2、NHCH2、反式乙烯基乙炔基;R1与环C连接在与A—B连接位置的邻位碳上,如本文所定义;n为1或2;R2和R3为烷基、卤代烷基或如本文所定义的环烷基或卤代环烷基;描述了制造用于提高温血动物(如人类)PDH活性的药物。还描述了公式(I)化合物的盐和酯。
  • Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
    申请人:——
    公开号:US20020198224A1
    公开(公告)日:2002-12-26
    The present invention is an efficient synthetic route to 2′,3′-dideoxy-2′,3 ′-didehydro-nucleosides from available precursors with the option of introducing functionality as needed, such as, the 2′,3′-dideoxy and 2′- or 3′-deoxyribo-nucleoside analogs as well as additional derivatives obtained by subsequent functional group manipulations. Briefly, the present invention discloses a method for the preparation of &bgr;-D and &bgr;-L-2′,3′-dideoxy-2′,3′-didehydro-nucleosides starting from appropriately substituted ribonucleosides in two, optionally three steps: Step (1) a haloacylation, such as haloacetylation, and in particular, bromoacetylation; Step (2) a reductive elimination; and optionally, Step (3) a deprotection. The haloacylation of step (1) can form the 2′-acyl-3′-halonucleoside, the 3′-acyl-2′-halonucleoside, or a mixture thereof.
    本发明提供了一种高效的合成路线,可以从可用的前体物开始合成2',3'-二脱氧-2',3'-二脱氢核苷,同时可以根据需要引入功能,例如2',3'-二脱氧和2'-或3'-脱氧核糖核苷类似物以及通过后续的官能团操作获得的额外衍生物。简而言之,本发明揭示了一种制备β-D和β-L-2',3'-二脱氧-2',3'-二脱氢核苷的方法,从适当取代的核糖核苷开始,在两个可选的步骤中进行:步骤(1)卤代酰化,例如卤代乙酰化,特别是代乙酰化;步骤(2)还原消除;可选地,步骤(3)去保护基。步骤(1)的卤代酰化可以形成2'-酰基-3'-卤代核苷,3'-酰基-2'-卤代核苷或它们的混合物。
  • 273. Derivatives of 6-aminopenicillanic acid. Part II. Trisubstituted acetyl derivatives
    作者:E. G. Brain、F. P. Doyle、K. Hardy、A. A. W. Long、M. D. Mehta、D. Miller、J. H. C. Nayler、M. J. Soulal、E. R. Stove、G. R. Thomas
    DOI:10.1039/jr9620001445
    日期:——
  • Ruechardt,C.; Brinkmann,H., Chemische Berichte, 1975, vol. 108, p. 3224 - 3242
    作者:Ruechardt,C.、Brinkmann,H.
    DOI:——
    日期:——
  • Ruechardt,C. et al., Chemische Berichte, 1975, vol. 108, p. 3210 - 3223
    作者:Ruechardt,C. et al.
    DOI:——
    日期:——
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-3-BOC-5-甲基-1,2,3-氧杂噻唑烷-2,2-二氧化物 (R)-2-苯基-3-羟基丙酸 (R)-2-羟基-2-(2-(2-(2-甲氧基-5-甲基吡啶-3-基)乙基)-琥珀酸 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4S)-4-叔丁基-1,2,3-氧杂噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S)-4-i-丙基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (4R)-4-叔丁基-1,2,3-氧杂噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S,3R)-2,3-二羟基-3-(2-吡啶基)丙酸乙酯,N-氧化物 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (2-三甲基甲硅烷基)-乙氧基甲基三氟硼酸钾 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 (11bR,11''bR)-2,2''-[氧双(亚甲基)]双[4-羟基-4,4''-二氧化物-二萘并[2,1-d:1'',2''-f][1,3,2]二氧磷杂七环 (11aR)-10,11,12,13-四氢-5-羟基-3,7-二-1-萘-5-氧化物-二茚基[7,1-de:1'',7''-fg][1,3,2]二氧杂磷杂八环 (1-氨基丁基)磷酸 (-)-N-[(2S,3R)-3-氨基-2-羟基-4-苯基丁酰基]-L-亮氨酸甲酯 齐特巴坦